PRINCETON, N.J., Jan. 30, 2020 /PRNewswire/ -- Soligenix,
Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage
biopharmaceutical company focused on developing and commercializing
products to treat rare diseases where there is an unmet medical
need, announced today that its President and Chief Executive
Officer, Christopher J. Schaber,
PhD, will deliver a corporate presentation reviewing the Company's
two Phase 3 clinical programs and pipeline at the 22nd
Annual BIO CEO & Investor Conference in New York City, Tuesday,
February 11, 2020 at 9:45 AM
EST. The presentation will take place at the New York
Marriott Marquis, Wilder Room, 4th Floor.
"This is clearly an exciting time for Soligenix with final
topline data for our Phase 3 cutaneous T-cell lymphoma program
expected this quarter followed by Phase 3 topline data in Oral
Mucositis next quarter," stated Christopher J. Schaber, PhD,
President and Chief Executive Officer of Soligenix. "The BIO CEO
conference comes at an opportune time as we continue to have
ongoing discussions with potential strategic partners and pursue
all options to advance our pipeline and plan for commercial
activities. We also look forward to meeting directly with high
caliber investment funds during the conference as well as potential
pharmaceutical partners."
If you are interested in arranging a one-on-one meeting, please
contact info@soligenix.com.
To access the Soligenix corporate presentation, please visit
here.
For more information about the BIO CEO & Investor
Conference, please refer to the conference website at
https://www.bio.org/events/bio-ceo-investor-conference.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on
developing and commercializing products to treat rare diseases
where there is an unmet medical need. Our Specialized
BioTherapeutics business segment is developing SGX301 as a novel
photodynamic therapy utilizing safe visible light for the treatment
of cutaneous T-cell lymphoma, our first-in-class innate defense
regulator (IDR) technology, dusquetide (SGX942) for the treatment
of oral mucositis in head and neck cancer, and proprietary
formulations of oral beclomethasone 17,21-dipropionate (BDP) for
the prevention/treatment of gastrointestinal (GI) disorders
characterized by severe inflammation including pediatric Crohn's
disease (SGX203) and acute radiation enteritis (SGX201).
Our Public Health Solutions business segment includes active
development programs for RiVax®, our ricin
toxin vaccine candidate, OrbeShield®, our
GI acute radiation syndrome therapeutic candidate and SGX943, our
therapeutic candidate for antibiotic resistant and emerging
infectious disease. The development of our vaccine programs
incorporates the use of our proprietary heat stabilization platform
technology, known as ThermoVax®. To
date, this business segment has been supported with government
grant and contract funding from the National Institute of Allergy
and Infectious Diseases (NIAID), the Defense Threat Reduction
Agents (DTRA) and the Biomedical Advanced Research and Development
Authority (BARDA).
For further information regarding Soligenix, Inc., please visit
the Company's website at www.soligenix.com.
This press release may contain forward-looking statements that
reflect Soligenix, Inc.'s current expectations about its future
results, performance, prospects and opportunities, including but
not limited to, potential market sizes, patient populations and
clinical trial enrollment. Statements that are not historical
facts, such as "anticipates," "estimates," "believes," "hopes,"
"intends," "plans," "expects," "goal," "may," "suggest," "will,"
"potential," or similar expressions, are forward-looking
statements. These statements are subject to a number of
risks, uncertainties and other factors that could cause actual
events or results in future periods to differ materially from what
is expressed in, or implied by, these statements. Soligenix
cannot assure you that it will be able to successfully develop,
achieve regulatory approval for or commercialize products based on
its technologies, particularly in light of the significant
uncertainty inherent in developing therapeutics and vaccines
against bioterror threats, conducting preclinical and clinical
trials of therapeutics and vaccines, obtaining regulatory approvals
and manufacturing therapeutics and vaccines, that product
development and commercialization efforts will not be reduced or
discontinued due to difficulties or delays in clinical trials or
due to lack of progress or positive results from research and
development efforts, that it will be able to successfully obtain
any further funding to support product development and
commercialization efforts, including grants and awards, maintain
its existing grants which are subject to performance requirements,
enter into any biodefense procurement contracts with the US
Government or other countries, that it will be able to compete with
larger and better financed competitors in the biotechnology
industry, that changes in health care practice, third party
reimbursement limitations and Federal and/or state health care
reform initiatives will not negatively affect its business, or that
the US Congress may not pass any legislation that would provide
additional funding for the Project BioShield program. In addition,
there can be no assurance as to timing or success of the Phase 3
clinical trial of SGX942 (dusquetide) as a treatment for oral
mucositis in patients with head and neck cancer receiving
chemoradiation therapy (including the outcome of the interim
analysis) or the Phase 3 clinical trial of SGX301 (synthetic
hypericin) for the treatment of cutaneous T-cell lymphoma.
Further, there can be no assurance that
RiVax® will qualify for a biodefense
Priority Review Voucher (PRV) or that the prior sales of PRVs will
be indicative of any potential sales price for a PRV for
RiVax®. These and other risk factors are
described from time to time in filings with the Securities and
Exchange Commission, including, but not limited to, Soligenix's
reports on Forms 10-Q and 10-K. Unless required by law,
Soligenix assumes no obligation to update or revise any
forward-looking statements as a result of new information or future
events.
View original
content:http://www.prnewswire.com/news-releases/soligenix-to-present-at-the-22nd-annual-bio-ceo--investor-conference-300995799.html
SOURCE Soligenix, Inc.